Eton Pharmaceuticals, Inc. (ETON) Financial Ratio Screen
Track ETON screening changes
Get an email when this stock's published screening status or underlying ratios change.
MSCI new-inclusion financial-ratio snapshot
ETON financial screening at a glance
Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Drug Manufacturers - Specialty & Generic) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: SEC filing extraction found 3 dimensioned facts; 0 have passed extraction review. No activity conclusion is made. Open the SEC annual filing.
View SEC-extracted business segments
- Product Sales And Royalties — 95.9% of filing total · extraction pending
- License — 4.1% of filing total · extraction pending
- Increlex — 2.2% of filing total · extraction pending
Profile description reviewed: Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 33.7% / 30% | 28.2% / 30% | 40.9% / 30% | N/A | INSUFFICIENT / NOT IMPLEMENTED* |
| S&P-style (provisional) | 8.7% / 33% | N/A | N/A | N/A | FINANCIAL SCREEN PASSED* |
| FTSE | 33.7% / 33% | 28.2% / 33% | 40.9% / 50% | N/A | INSUFFICIENT / NOT IMPLEMENTED* |
Financial Highlights
Profitability
| Gross Margin | 61.4% | |
| Operating Margin | 35.8% | |
| Net Margin | 12.0% | |
| Return on Equity (ROE) | 36.0% | |
| Return on Assets (ROA) | 11.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $11M |
| Free Cash Flow | $10M |
| Total Debt | $31M |
| Debt-to-Equity | 62.7 |
| Current Ratio | 1.5 |
| Total Assets | $92M |
Price & Trading
| Last Close | $59.91 |
| 50-Day MA | $42.04 |
| 200-Day MA | $26.09 |
| Avg Volume | 525K |
| Beta | 0.9 |
|
52-Week Range
$14.27
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-08-24 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- SEC EDGAR filing search — primary filing source for US issuers.
- Field mapping, formulas and limitations.
Historical market-cap evidence
37 monthly estimates are retained from
2023-07-31 to
2026-07-31. Each point combines a
month-end close from
Nasdaq public historical endpoint
with an SEC-reported share count. The
latest share evidence is dated
2026-05-12
(10-Q,
tag dei:EntityCommonStockSharesOutstanding,
accession 0001437749-26-017064).
Open SEC XBRL evidence.
Open Nasdaq price evidence.
When 36 completed months are available, these observations support
a provisional independent S&P-style leverage calculation.
This reconstruction is not official S&P index data, does not prove
index membership, and does not complete the separate activity-income
screen. DJIM remains unavailable.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About Eton Pharmaceuticals, Inc. (ETON)
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is Eton Pharmaceuticals, Inc. (ETON) halal to invest in?
The current automated result is More financial data is needed. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is Eton Pharmaceuticals, Inc.'s debt ratio?
Eton Pharmaceuticals, Inc.'s debt ratio is 33.7% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are Eton Pharmaceuticals, Inc.'s key financial metrics?
Eton Pharmaceuticals, Inc. has a market capitalization of USD 1814M in its listing currency, trailing P/E ratio of 162.7, and revenue of $80M. The company maintains a gross margin of 61.4% and a net margin of 12.0%. Return on equity stands at 36.0%.
How often is the screening data updated?
Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.